This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Glaucoma

To Study the Function of the Retina in Glaucoma Patients Using PERG

Sponsored by Swiss Vision Network

About this trial

Last updated 3 years ago

Study ID

PERG-01

Status

Enrolling by invitation

Type

Observational

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Trial Timing

Ended 2 years ago

What is this trial about?

The purpose of this trial is to evaluate the performance of a new diagnostic device in the diagnosis and management of glaucoma. We will use this new device (PERG) to evaluate the function of the retina in glaucoma patients. This device is safe for the patients.

What are the participation requirements?

Yes

Inclusion Criteria

- Glaucoma (all types of glaucoma);

- Ocular hypertensive (Suspicion of glaucoma);

- Control Patients (without any suspicion/sign of glaucoma);

- Have given written informed consent, prior to any investigational procedures;

- Aged 18 years of either sex.

No

Exclusion Criteria

- Patients not able to understand the character of the study

- Participation in other clinical research within the last 4 weeks

- Other diseases that may cause visual field loss or optic disc abnormalities

- Systemic diseases that may affect PERG amplitude such as diabetes, parkinsonism, multiple sclerosis

- Poor best corrected visual acuity outside the limits recommended for the test

- Patients with high myopia (>5D)